Boston Scientific Sees 8 Insiders Exercise Options Worth $982K in One Week
Eight Boston Scientific Corporation (NYSE: BSX) executives exercised stock options and conducted related tax payments totaling $982,176 over a concentrated four-day period from February 13 to February 16, 2026, according to SEC filings.
The Trades
The cluster of insider activity involved 16 separate transactions, split evenly between option exercises and tax-related share dispositions. All tax payments occurred at a uniform price of $74.73 per share, suggesting coordinated vesting events or a structured compensation plan milestone.
The total value of $982,176 represents only the tax payment portions of these transactions, as the exercise prices for the options were not disclosed in the filings. This indicates the actual economic value of the options exercised was substantially higher, with the nearly $1 million figure representing just the tax obligations on these equity awards.
The timing concentration is notable — all transactions occurred within a four-day window, with the bulk happening on February 13, 14, and 16. This pattern typically indicates a scheduled vesting date for restricted stock units or the opening of a trading window following earnings announcements.
Who's Trading
Four senior executives participated in this trading cluster, each following an identical pattern of exercising options across three separate days:
Padraig Andrew O'Connor, Executive Vice President of Global Operations, exercised 2,595 shares total and sold 987 shares for tax payments totaling $73,759. His transactions represented the smallest dollar volume among the group.
Emily Woodworth, Senior Vice President, Global Controller and Chief Accounting Officer, exercised 2,711 shares and disposed of 1,269 shares for $94,832 in tax obligations. As the company's chief accounting officer, her participation in this coordinated activity suggests routine compensation events rather than discretionary trading.
Jonathan Monson, Executive Vice President and Chief Financial Officer, had the largest transaction volume, exercising 3,814 shares and selling 1,698 shares for tax payments of $126,891. The CFO's higher transaction values align with typical executive compensation hierarchies.
Miriam O'Sullivan, Senior Vice President and Chief Human Resources Officer, participated with smaller transactions, exercising 588 shares and selling 200 shares for $14,946 in tax payments. The filing data appears incomplete for O'Sullivan, showing only transactions from February 13.
All four executives hold critical operational and financial oversight roles at Boston Scientific, making their coordinated activity particularly noteworthy for investors monitoring insider sentiment.
What to Watch
This cluster of insider transactions presents several key observations for investors. First, the uniform tax payment price of $74.73 across all transactions provides a clear benchmark for how insiders value their shares for tax purposes. The fact that executives chose to sell shares to cover taxes rather than pay cash could indicate either standard company policy or individual liquidity preferences.
The concentration of activity suggests these transactions stem from a predetermined vesting schedule rather than discretionary trading decisions. This is reinforced by the consistent pattern — each executive (except O'Sullivan) executed transactions on the same three dates, likely corresponding to a tiered vesting structure.
Importantly, these appear to be option exercises with tax-related sales, not outright stock sales. Executives are acquiring shares through options and only selling enough to cover tax obligations, which is generally viewed as less bearish than discretionary selling. The retention of the remaining shares after tax payments suggests continued confidence in Boston Scientific's prospects.
For context, Boston Scientific's stock has shown strength in recent months, and these transactions at $74.73 should be evaluated against the company's current trading levels and recent financial performance. The coordinated nature and operational focus of the executives involved — spanning operations, finance, accounting, and human resources — indicates this is likely part of Boston Scientific's regular equity compensation program rather than a signal about company fundamentals.
Investors should monitor whether additional insiders participate in similar transactions in the coming days, as extended insider selling beyond routine vesting events could warrant closer scrutiny. However, the current pattern appears consistent with standard executive compensation practices at large medical device companies.
*Source: SEC Form 4 filings*
*By StockCliff Research*